HIMS · Hims & Hers Health, Inc.

The thesis

Hims & Hers Health's recovery case depends on third-quarter revenue reaching the company's $880–900 million guide. Card data published on 8 October 2026 showed a sharp September slowdown in weight-loss billings, so the case is weaker than it was. The third-quarter report, expected around 9 November 2026 but not yet confirmed by the company, settles it.

The shares closed at $30.92 on 9 October 2026 in adjusted daily closes. That is 50.7% below the $62.76 52-week high and 12.0% lower over three months. The narrative is maturing: the August revenue reset is well known, and news since the 27 September 2026 note has been a securities class action, a September billing slowdown and lists of heavy options trading, with no company news. A weekly close below $27.51, the 11 September 2026 close, would break the repair case.

Bullish and bearish views on Hims & Hers Health, Inc.

The bull case on Hims & Hers Health, Inc. (HIMS), in brief: The second quarter beat the guide. The bear case: September weight-loss billings fell sharply.

Bull case

• The second quarter beat the guide. Hims & Hers reported second-quarter 2026 revenue of $753.2 million on 10 August 2026, up 38% year over year and above its $680–700 million guide. Company results
• Card data shows quarter-over-quarter growth. Truist's card data, reported by Investing.com on 8 October 2026, showed third-quarter GLP-1 (weight-loss drug) billings up 22% from the second quarter, with transactions up 21%. That growth fits management's higher third-quarter guide. Investing.com
• Subscribers and spending both rose. The company reported 2.891 million subscribers at 30 June 2026, up 19% year over year. Monthly revenue per average subscriber was $92 in the second quarter, up 21%. Company results

Bear case

• September weight-loss billings fell sharply. Truist's card data showed GLP-1 billings down 16% month over month per day in September, after a 1% rise in August. Average customer duration fell to 1.12 months from 1.26 months, according to Investing.com's 8 October 2026 report. Investing.com
• Growth came with weaker margins. Second-quarter gross margin was 64%, down from 76% a year earlier, and the GAAP net loss was $86.3 million, the company said on 10 August 2026. Investing.com's 8 October 2026 report said Barclays cut its price target to $35, citing margin pressure.
• Legal exposure is widening. The Federal Trade Commission (FTC), California and Utah sued on 29 July 2026 over alleged privacy, billing and cancellation practices. A securities class action against the company and certain executives followed, announced in a PR Newswire release dated 6 October 2026. PR Newswire
• The card-dispute problem is unresolved. Bloomberg reported on 21 August 2026 that July weight-loss subscription disputes exceeded Visa's 1.5% monitoring threshold. Leaving the program takes three straight months below that rate, and the company has not disclosed meeting it.

Price setup

The shares closed at $30.92 on 9 October 2026, after $29.42 on 25 September 2026 and $27.51 on 11 September 2026. That is a series of higher closes from the September low area. The 14-day relative strength index (RSI) stood at 56.5 on 9 October 2026, a neutral reading. The shares remain 50.7% below the $62.76 52-week high.

Analysts are mostly neutral. Truist repeated a Hold rating with a $32 target on 8 October 2026, and JPMorgan started coverage at Hold with a $32 target on 11 September 2026. StockAnalysis puts the average target from 15 analysts at $31.23, with a range of $23 to $42, so the last close sits just under consensus.

Benzinga's options-activity lists named the stock on 18 September 2026, 09-21, 09-24, 09-25, 09-30 and 10-05, which shows heavy speculative attention. The expected report date adds event risk inside the next 30 days.

Catalysts, next 30 days

• ~9 November 2026, est. third-quarter 2026 results. The company had not confirmed the date as of 9 October 2026. Revenue against the $880–900 million guide, adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) against the $75–95 million guide, and gross margin against the second quarter's 64% decide the case.
• Early November, est. October card-data updates. A rebound in GLP-1 billings after September's 16% per-day decline would ease the retention concern. A further drop would point to a weak fourth-quarter guide.
• Date not set — FTC and class-action proceedings. Any order or settlement that changes checkout or cancellation would test whether subscriber growth holds up under a different sign-up flow.

What would change the view

Third-quarter revenue below the $880 million guide floor would break the case. So would gross margin below the second quarter's 64%, or a fourth-quarter outlook that shows September's billing slowdown carrying forward. A court order or settlement forcing changes to checkout or cancellation, followed by slower subscriber growth than the second quarter's 19%, would also break it.

The case would get stronger if third-quarter revenue lands at or above $900 million with margins steady. A rebound in October card data showing longer customer duration would help, as would a disclosure that Visa dispute rates are back under 1.5%. A weekly close below $27.51 would end the repair case on price alone.

What it trades with

The biggest moves in the past three months came from company events: the 29 July 2026 FTC complaint, the 10 August 2026 report and the 21 August 2026 Visa report. Broader market swings mattered less. The shares also react to branded GLP-1 pricing and distribution news from Novo Nordisk, Eli Lilly and large pharmacy or retail entrants, because Hims & Hers' weight-loss revenue competes with those channels. Heavy options trading tends to make moves bigger in both directions around the report.